Invasive aspergillosis in solid organ transplant recipients

American Journal of Transplantation

Volumn 9, Issue SUPPL. 4, 2009, Pages

  Singh, N ^a   Husain, S ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Aspergillosis; Prophylaxis; Solid organ transplant; Treatment

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A4; ECHINOCANDIN; GALACTOMANNAN; GAMMA INTERFERON; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; ISOENZYME; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS TERREUS; BLOOD CULTURE; BRONCHOSPASM; CANDIDEMIA; CANDIDIASIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; COUGHING; CYTOMEGALOVIRUS INFECTION; DEBRIDEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; FUNGUS CULTURE; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT RECIPIENT; GROUPS BY AGE; HEART GRAFT; HEMOFILTRATION; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RATE; INFECTION RISK; INTENSIVE CARE UNIT; KIDNEY FAILURE; KIDNEY GRAFT; LABORATORY DIAGNOSIS; LENGTH OF STAY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER GRAFT; LIVER TOXICITY; LOADING DRUG DOSE; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG RESECTION; MORBIDITY; MORTALITY; NAUSEA; NEUTROPHIL; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PREVALENCE; PRIORITY JOURNAL; RECURRENT INFECTION; RENAL REPLACEMENT THERAPY; RESPIRATORY SYSTEM; RETRANSPLANTATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; SURVIVAL RATE; TRACHEOBRONCHITIS; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; URINARY EXCRETION;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 72949120623     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02910.x     Document Type: Review

References (123)

1. Morgan J, Wannemuehler KA, Marr KA et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med Mycol 2005 43 (Suppl 1 S49 S58.
2. Singh N, Arnow PM, Bonham A et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997 64 : 716 720. (Pubitemid 27407098)
3. Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003 36 : 46 52.
4. Gavalda J, Len O, San JR et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis 2005 41 : 52 59.
5. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999 78 : 123 138.
6. Brown RS Jr., Lake JR, Katzman BA et al. Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation 1996 61 : 666 669.
7. Briegel J, Forst H, Spill B et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995 14 : 375 382.
8. Kusne S, Torre-Cisneros J, Manez R et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992 166 : 1379 1383.
9. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005 18 : 44 69.
10. Fortun J, Martin-Davila P, Moreno S et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002 8 : 1065 1070.
11. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001 71 : 910 913.
12. Singh N, Limaye AP, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006 81 : 320 326.
13. Osawa M, Ito Y, Hirai T et al. Risk factors for invasive aspergillosis in living donor liver transplant recipients. Liver Transpl 2007 13 : 566 570.
14. George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997 103 : 106 113.
15. Collins LA, Samore MH, Roberts MS et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994 170 : 644 652.
16. Selby R, Ramirez CB, Singh R et al. Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression. Arch Surg 1997 132 : 304 310.
17. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996 23 : 608 615.
18. Fortun J, Martin-Davila P, Moreno S et al. Prevention of invasive fungal infections in liver transplant recipients: The role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003 52 : 813 819.
19. Altiparmak MR, Apaydin S, Trablus S et al. Systemic fungal infections after renal transplantation. Scand J Infect Dis 2002 34 : 284 288.
20. Cofan F, Ricart MJ, Oppenheimer F et al. Study of kidney rejection following simultaneous kidney-pancreas transplantation. Nephron 1996 74 : 58 63. (Pubitemid 26300650)
21. Weiland D, Ferguson RM, Peterson PK, Snover DC, Simmons RL, Najarian JS. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management. Ann Surg 1983 198 : 622 629.
22. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH Jr. Invasive aspergillosis in renal transplant recipients: Correlation with corticosteroid therapy. J Infect Dis 1983 148 : 230 238.
23. Peterson PK, Ferguson R, Fryd DS, Balfour HH Jr., Rynasiewicz J, Simmons RL. Infectious diseases in hospitalized renal transplant recipients: A prospective study of a complex and evolving problem. Medicine (Baltimore) 1982 61 : 360 372.
24. Gallis HA, Berman RA, Cate TR, Hamilton JD, Gunnells JC, Stickel DL. Fungal infection following renal transplantation. Arch Intern Med 1975 135 : 1163 1172.
25. Panackal AA, Dahlman A, Keil KT et al. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation 2003 75 : 1050 1053.
26. Husain S, Paterson DL, Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006 6 : 3008 3016. (Pubitemid 44777932)
27. Husain S. Differences in invasive aspergillosis in solid organ transplant recipients. http://www.aspergillus.org.uk/indexhome.htm?secure/conferences/ index.php∼main-last. Accessed on January 10, 2009. 2008.
28. Chan KM. Approach towards infectious pulmonary complications in lung tramnsplant recipients. In : Singh N, Aguado JM, eds. Infectious complications in transplant aptients, 1st Ed. Kluwer Academic publishers, 2001 : 149 175.
29. Higgins R, McNeil K, Dennis C et al. Airway stenoses after lung transplantation: Management with expanding metal stents. J Heart Lung Transplant 1994 13 : 774 778.
30. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996 61 : 915 919.
31. Goldfarb NS, Avery RK, Goormastic M et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001 71 : 242 246.
32. Cresp, Raza K, Studer S, Pilewski JL, McCurry K, Husain S. Risk of pulmonary aspergillosis after bronchial stent placement in lung transplant (LTx) recipients. 26th Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation. Madrid, Spain. 2006. 2009.
33. Husni RN, Gordon SM, Longworth DL et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998 26 : 753 755.
34. Cahill BC, Hibbs JR, Savik K et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997 112 : 1160 1164.
35. Nunley DR, Ohori P, Grgurich WF et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998 114 : 1321 1329.
36. Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC. Aspergillus infection in lung transplant recipients with cystic fibrosis: Risk factors and outcomes comparison to other types of transplant recipients. Chest 2003 123 : 800 808.
37. Munoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections: Should a combination of antifungal drugs be used? Curr Opin Infect Dis 2006 19 : 365 370.
38. Berenguer J, Munoz P, Parras F, Fernandez-Baca V, Hernandez-Sampelayo T, Bouza E. Treatment of deep mycoses with liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 1994 13 : 504 507.
39. Munoz P, Rodriguez C, Bouza E et al. Risk factors of invasive aspergillosis after heart transplantation: Protective role of oral itraconazole prophylaxis. Am J Transplant 2004 4 : 636 643.
40. Munoz P, Alcala L, Sanchez CM et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation 2003 75 : 326 329.
41. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP III. Spectrum of Aspergillus infection in lung transplant recipients: Case series and review of the literature. Chest 2001 119 : 169 175.
42. Fortun J, Martin-Davila P, Alvarez ME et al. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001 71 : 145 149.
43. Kwak EJ, Husain S, Obman A et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004 42 : 435 438. (Pubitemid 38082765)
44. Husain S, Kwak EJ, Obman A et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004 4 : 796 802. (Pubitemid 38637580)
45. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 2006 42 : 1417 1727.
46. Husain S, Paterson DL, Studer SM et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007 83 : 1330 1336.
47. Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007 45 : 1759 1765.
48. Husain S, Clancy CJ, Nguyen MH et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 2008 15 : 1760 1763.
49. Kawagishi N, Satoh K, Enomoto Y et al. Risk factors and impact of beta-D glucan on invasive fungal infection for the living donor liver transplant recipients. Tohoku J Exp Med 2006 209 : 207 215.
50. Badiee P, Kordbacheh P, Alborzi A, Malekhoseini SA. Invasive fungal infection in renal transplant recipients demonstrated by panfungal polymerase chain reaction. Exp Clin Transplant 2007 5 : 624 629.
51. Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant recipients: Outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis 2003 37 : 17 25.
52. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 415. (Pubitemid 34851833)
53. Fortun J, Martin-Davila P, Sanchez MA et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003 22 : 408 413.
54. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 34 : 563 571.
55. Veroux M, Corona D, Gagliano M et al. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients. Transplant Proc 2007 39 : 1838 1840. (Pubitemid 47198782)
56. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005 106 : 2641 2645.
57. Weclawiak H, Garrouste C, Kamar N et al. Aspergillus fumigatus-related spondylodiscitis in a heart transplant patient successfully treated with voriconazole. Transplant Proc 2007 39 : 2627 2628.
58. Wieland T, Liebold A, Jagiello M, Retzl G, Birnbaum DE. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation. J Heart Lung Transplant 2005 24 : 102 104.
59. Kramer M, Kramer MR, Blau H, Bishara J, Xer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006 113 : 1184 1186.
60. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 46 : 327 360.
61. Groetzner J, Kaczmarek I, Wittwer T et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 2008 27 : 1 6.
62. Carby MR, Hodson ME, Banner NR. Refractory pulmonary aspergillosis treated with caspofungin after heart-lung transplantation. Transpl Int 2004 17 : 545 548.
63. Forestier E, Remy V, Lesens O et al. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole. Eur J Clin Microbiol Infect Dis 2005 24 : 347 349.
64. Shlobin OA, Dropulic LK, Orens JB et al. Mediastinal mass due to Aspergillus fumigatus after lung transplantation: A case report. J Heart Lung Transplant 2005 24 : 1991 1994.
65. Vagefi PA, Cosimi AB, Ginns LC, Kotton CN. Cutaneous Aspergillus ustus in a lung transplant recipient: Emergence of a new opportunistic fungal pathogen. J Heart Lung Transplant 2008 27 : 131 134.
66. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
67. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006 53 : 337 349.
68. Lodge BA, Ashley ED, Steele MP, Perfect JR. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol 2004 42 : 1376 1378.
69. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007 44 : 1289 1297.
70. Sole A, Morant P, Salavert M, Peman J, Morales P. Aspergillus infections in lung transplant recipients: Risk factors and outcome. Clin Microbiol Infect 2005 11 : 359 365.
71. Anonymous. Voriconazole. Med Lett Drug Ther 2002 44 : 63 65.
72. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008 8 : 426 431.
73. Rea F, Marulli G, Loy M et al. Salvage right pneumonectomy in a patient with bronchial-pulmonary artery fistula after bilateral sequential lung transplantation. J Heart Lung Transplant 2006 25 : 1383 1386.
74. Scherer M, Fieguth HG, Aybek T, Ujvari Z, Moritz A, Wimmer-Greinecker G. Disseminated Aspergillus fumigatus infection with consecutive mitral valve endocarditis in a lung transplant recipient. J Heart Lung Transplant 2005 24 : 2297 2300.
75. Hummel M, Schuler S, Weber U et al. Aspergillosis with Aspergillus osteomyelitis and diskitis after heart transplantation: Surgical and medical management. J Heart Lung Transplant 1993 12 : 599 603.
76. Loria KM, Salinger MH, Frohlich TG, Gendelman MD, Cook FV, Arentzen CE. Primary cutaneous aspergillosis in a heart transplant recipient treated with surgical excision and oral itraconazole. J Heart Lung Transplant 1992 11 (1 Pt 1 156 159.
77. Sandur S, Gordon SM, Mehta AC, Maurer JR. Native lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation: A case report. J Heart Lung Transplant 1999 18 : 810 813.
78. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006 26 : 1730 1744.
79. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006 12 : 325 334.
80. Wimberley SL, Haug MT III., Shermock KM et al. Enhanced cyclosporine-itraconazole interaction with cola in lung transplant recipients. Clin Transplant 2001 15 : 116 122.
81. Marty FM, Bryar J, Browne SK et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: A cohort analysis. Blood 2007 110 : 490 500.
82. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: A report of two cases. Transplant Proc 2004 36 : 2708 2709.
83. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007 27 : 825 834.
84. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002 4 : 25 30.
85. Saner F, Gensicke J, Rath P et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006 34 : 328 332.
86. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004 34 : 13 20.
87. Anttila VJ, Piilonen A, Valtonen M. Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection. Scand J Infect Dis 2003 35 : 893 894.
88. Vazquez JA, Sobel JD. Anidulafungin: A novel echinocandin. Clin Infect Dis 2006 43 : 215 222.
89. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005 45 : 227 233.
90. Joseph JM, Jain R, Danziger LH. Micafungin: A new echinocandin antifungal. Pharmacotherapy 2007 27 : 53 67.
91. Hebert MF, Townsend RW, Austin S et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005 45 : 954 960.
92. Chandrasekar PH, Sobel JD. Micafungin: A new echinocandin. Clin Infect Dis 2006 42 : 1171 1178.
93. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005 191 : 1180 1187. (Pubitemid 40404378)
94. Vora S, Chauhan S, Brummer E, Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998 42 : 2299 2303. (Pubitemid 28420368)
95. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 1992 327 : 99 106.
96. Dale DC, Liles WC, Summer WR, Nelson S. Review: Granulocyte colony-stimulating factor - role and relationships in infectious diseases. J Infect Dis 1995 172 : 1061 1075.
97. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 1999 179 (Suppl 2 S342 S352.
98. Rowe JM, Andersen JW, Mazza JJ et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995 86 : 457 462.
99. Gaviria JM, van Burik JA, Dale DC, Root RK, Liles WC. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999 179 : 1038 1041.
100. Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996 34 : 63 69.
101. Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995 172 : 1554 1560.
102. Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991 163 : 849 852.
103. Summers SA, Dorling A, Boyle JJ, Shaunak S. Cure of disseminated cryptococcal infection in a renal allograft recipient after addition of gamma-interferon to anti-fungal therapy. Am J Transplant 2005 5 : 2067 2069.
104. Mamishi S, Zomorodian K, Saadat F, Gerami-Shoar M, Tarazooie B, Siadati SA. A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-gamma. Ann Clin Microbiol Antimicrob 2005 4 : 4.
105. Saulsbury FT. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001 32 : E137 E139.
106. Pasic S, Abinun M, Pistignjat B et al. Aspergillus osteomyelitis in chronic granulomatous disease: Treatment with recombinant gamma-interferon and itraconazole. Pediatr Infect Dis J 1996 15 : 833 834.
107. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis. Liver Transpl 2006 12 : 850 858.
108. Hellinger WC, Bonatti H, Yao JD et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005 11 : 656 662.
109. Reed A, Herndon JB, Ersoz N et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 2007 13 : 1743 1750.
110. Singhal S, Ellis RW, Jones SG et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl 2000 6 : 588 595.
111. Fortun J, Martin-Davila P, Montejo M et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009 87 : 424 435.
112. Borro JM, Sole A, de la TM et al. Efficiency and safety of inhaled amphotericin B lipid complex (abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008 40 : 3090 3093.
113. Drew RH, Dodds AE, Benjamin DK Jr., Duane DR, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004 77 : 232 237.
114. Minari A, Husni R, Avery RK et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002 4 : 195 200.
115. Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: Study of risk factors. J Heart Lung Transplant 2001 20 : 1274 1281.
116. Monforte V, Roman A, Gavalda J et al. Nebulized liposomal amphotericin B (n-LAB) prophylaxis for aspergillus infection in lung transplantation (LT): Pharmacokinetics, safety and efficacy. J Heart Lung Transplant 2009 28 : 170 175.
117. Calvo V, Borro JM, Morales P et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999 115 : 1301 1304.
118. Reichenspurner H, Gamberg P, Nitschke M et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997 29 : 627 628.
119. Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J 1999 13 : 180 186.
120. Palmer SM, Drew RH, Whitehouse JD et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001 72 : 545 548.
121. Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003 75 : 1571 1574.
122. Wahidi MM, Willner DA, Snyder LD, Hardison JL, Chia JY, Palmer SM. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest 2009 135 : 484 491.
123. Cadena J, Levine DJ, Angel LF et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: Hepatotoxicity and effectiveness. Am J Transplant 2009 9 : 2085 2091.